Abemaciclib is in clinical development as an adjuvant treatment for patients with early breast cancer who have undergone surgery. Early breast cancer is where the disease is limited to the breast region and has not spread to other parts of the body. Symptoms include swelling of breast regions, breast or nipple pain, nipple retraction, change in texture of skin covering the breast, nipple discharge and swollen lymph nodes. Treatment of early stage breast cancer usually involves surgery. Most patients will often receive some treatment after (‘adjuvant’) the surgery to improve the success rate of the treatment.
Abemaciclib is an oral cancer medicine. It works by blocking the activity of certain enzymes known as cyclin-dependant kinases (CDK) 4 and 6, which play a key role in regulating the way cells grow and divide. By blocking these enzymes, abemaciclib slows the growth of breast cancer cells. If licenced, abemaciclib will provide an additional treatment option for patients with early breast cancer who have undergone surgery.
Pembrolizumab in addition to chemotherapy, followed by maintenance with olaparib is in clinical development for the first line treatment of Breast Cancer Gene (BRCA) non-mutated advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Ovarian cancer includes a group of tumours that arise from diverse types of tissue contained in the ovary and can often spread from the ovary to any surface within the abdominal cavity including the fallopian tubes and peritoneal cavity. While current treatments exist for these advanced cancers of the female reproductive system, significant unmet medical need remains for more effective treatment options with manageable safety profiles for patients in the first line setting.